Edenred revenue from operations was flat as reported at €667 million in the third quarter of 2026, while declining 1.2% on a like-for-like basis. In its October 21 announcement, the employee-benefits and mobility services group maintained its full-year guidance as meal-benefit regulatory changes in Italy and Brazil weighed on the business.
Key Takeaways
- Third-quarter operating revenue showed 6.6% intrinsic growth, contrasting with the decline on a like-for-like basis.
- Edenred maintained its forecast for a 7%–10% like-for-like EBITDA decline in 2026.
- Management reaffirmed its outlook for 8%–12% like-for-like EBITDA growth in both 2027 and 2028.
Table of Contents
- Edenred revenue measures show different growth pictures
- Annual outlook still incorporates a profit decline
- Management maintains its 2027–2028 recovery targets
- Conclusion
Edenred revenue measures show different growth pictures
Edenred’s third-quarter revenue announcement showed double-digit like-for-like growth in Mobility and mid-single-digit intrinsic growth in Benefits & Engagement. Chief Executive Bertrand Dumazy said the latter performance excluded the impact of Meal & Food regulatory changes in Brazil and Italy.
The distinction between the measures matters: the company’s 6.6% intrinsic growth figure does not mean that reported quarterly operating revenue increased. Reported revenue was unchanged from the third quarter of 2025, while the like-for-like measure was negative.
For the nine months ended September 30, 2026, operating revenue increased 1.1% as reported and 0.6% like for like. Edenred put intrinsic operating revenue growth for that period at 7.6%.
| Item | Details |
|---|---|
| Nine-month operating revenue | €2,027 million |
| Nine-month other revenue | €171 million, unchanged from the first nine months of 2025 |
| Nine-month total revenue | €2,198 million, up 1.0% as reported and 0.6% like for like |
| Full-year 2026 other revenue outlook | At least €210 million now expected |
Annual outlook still incorporates a profit decline
Edenred described 2026 as a rebasing year in the context of the Meal & Food regulatory reset in Italy and Brazil. Its maintained guidance calls for a like-for-like EBITDA decline of between 10% and 7%, rather than a return to profit growth this year.
The corresponding EBITDA range is approximately €1.22 billion to €1.26 billion. Edenred updated that euro-denominated range to account for the scope effects of transactions completed in the third quarter, while retaining the like-for-like decline forecast.
Management also maintained its target for free cash flow equal to at least 35% of EBITDA in 2026. That is a forward-looking cash-conversion target, not a reported nine-month result.
Management maintains its 2027–2028 recovery targets
Beyond the current year, Edenred reaffirmed expectations for like-for-like EBITDA growth of 8%–12% in each of 2027 and 2028, with free cash flow conversion of at least 65% of EBITDA.
The company is pursuing its Amplify 25-28 strategy through distribution partnerships, cross-selling and technology investment. It highlighted a new Benefits & Engagement distribution partnership in France using its Edenred+ platform, alongside cross-selling opportunities in Mexico and upselling in Japan.
These initiatives form part of management’s plans to restore growth; the longer-term EBITDA and cash-conversion figures remain targets rather than achieved results.
Conclusion
Full-year 2026 performance is the next test of Edenred’s maintained EBITDA and cash-conversion guidance. Its outlook continues to place the return to EBITDA growth in 2027, not in the current year.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
